犬関節炎治療薬の世界市場

Future Market Insightsが発行した調査報告書（FUMI809269）

◆英語タイトル：Canine Arthritis Treatment Market: Asia Pacific Excluding Japan to Register the Fastest Growth During the Forecast Period: Global Industry Analysis (2013 - 2017) and Opportunity Assessment (2018 - 2028)
◆商品コード：FUMI809269
◆発行会社（リサーチ会社）：Future Market Insights
◆発行日：2018年7月26日
◆ページ数：260
◆レポート形式：英語 / PDF
◆納品方法：Eメール
◆調査対象地域：グローバル
◆産業分野：医療・医薬品・医療機器
◆販売価格オプション（消費税別）

Individual Price（1名様閲覧用）	USD5,000 ⇒換算￥565,000	見積依頼/購入/質問フォーム
Corporate Price（同一法人内共有可）	USD7,500 ⇒換算￥847,500	見積依頼/購入/質問フォーム

★Future Market Insightsに受託調査の見積を依頼する

※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はFuture Market Insights社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。Future Market Insights社の概要及び新刊レポートはこちらでご確認いただけます。

※本調査レポートでは、犬関節炎治療薬の世界市場について調査・分析し、以下の構成でお届けいたします。
・犬関節炎治療薬の世界市場の世界市場概観
・犬関節炎治療薬の世界市場の世界市場規模
・犬関節炎治療薬の世界市場の世界市場予測
・犬関節炎治療薬の世界市場の世界市場：地域別市場分析
・犬関節炎治療薬の世界市場のアメリカ市場規模
・犬関節炎治療薬の世界市場のヨーロッパ市場規模
・犬関節炎治療薬の世界市場のアジア市場規模
・犬関節炎治療薬の世界市場の世界市場：セグメント別市場分析
・犬関節炎治療薬の世界市場の世界市場：競争状況
・犬関節炎治療薬の世界市場の世界市場：市場動向
・犬関節炎治療薬の世界市場の世界市場：関連企業分析

【レポートの概要】

Future Market Insights (FMI) offers a 10-year forecast on the global canine arthritis treatment market. The primary objective of the report is to offer updates and information related to market opportunities in the canine arthritis treatment market.

Report Description

In terms of revenue, the global canine arthritis treatment market is expected to register a CAGR of 4.4% during the forecast period, 2018–2028. The primary objective of the report is to offer insights on the market dynamics that can influence the growth of the global canine arthritis treatment market over the forecast period. Insights on key trends, drivers, restraints, value forecasts and opportunities for companies operating in the global canine arthritis treatment market are presented in the report.

The global market for canine arthritis treatment is expected to witness high growth rate in terms of value in high economic countries due to fast FDA approvals for novel and innovative canine arthritis treatment drugs coupled with growing adoption of stem therapy to treat arthritis. Additionally, huge investments in the research and development sector for the development of advanced stem cell therapy and drugs for arthritis in countries such as the U.S., Germany, France and U.K. is expected to create numerous opportunities for the manufacturers of canine arthritis treatment products. Manufacturers are focusing on the production of high-grade drugs with less side effects due to its high demand from end users.

The report includes canine arthritis treatment drugs such as non-steroidal anti-inflammatory medications (NSAIDs) and opioids. Also, the stem cell therapy is taken into account along with drugs to calculate revenue generation in the canine arthritis treatment market.

However, the report does not include revenue generated by the sale of other medical products such as prosthetics and medical devices. Currency fluctuations and inflation are not considered while calculating the revenue of the canine arthritis treatment market

Revenue from the canine arthritis treatment market in North America is expected to expand at the relatively higher CAGR due to growing adoption of drugs and therapies and increased consumer spending on veterinary care. To understand and assess the opportunities in this market, the report offers the market forecast on the basis of segment type classified into the treatment type, route of administration, end users and regions. The report provides analysis of the global canine arthritis treatment market in terms of market value (US$ Mn).

The global canine arthritis treatment market is segmented on the basis of treatment type into:

Non-steroidal anti-inflammatory drugs
Opioids
Stem Cell Therapy
The report begins with the market definition of canine arthritis treatment, followed by definitions of the different treatment types. The market dynamics section includes FMI’s analysis on key trends, drivers, restraints, opportunities and macro-economic factors influencing the growth of the global canine arthritis treatment market.

The report analyses the canine arthritis treatment market on the basis of the route of administration and end users and presents forecast in terms of value for the next 10 years. On the basis of route of administration, the global canine arthritis treatment market is segmented into:

Oral

Injectable

On the basis of the end users, the global canine arthritis treatment market is segmented into:

Veterinary Hospitals and Clinics

Retail Pharmacies

Drug Stores

E-commerce

Next, the report analyses the market on the basis of regions and presents forecast in terms of value for the next 10 years. On the basis of region, the global canine arthritis treatment market is segmented into:

North America

U.S.

Canada

Latin America

Brazil

Mexico

Rest of Latin America

Europe

Germany

France

U.K.

Italy

Spain

Russia

Rest of Europe

Asia Pacific

India

China

Australia & New Zealand

ASEAN

Rest of APEJ

Japan

Middle East & Africa (MEA)

GCC Countries

South Africa

Rest of MEA

In addition, we have considered Year-on-Year (Y-o-Y) growth to understand the predictability of the market and identify growth opportunities for companies operating in the global canine arthritis treatment market.

Another key feature of this report is the analysis of key segments in terms of absolute dollar opportunity. This is usually overlooked while forecasting the market. However, absolute dollar opportunity is critical for assessing the level of opportunity that a provider can look to achieve, as well as to identify potential resources from a sales and delivery perspective for services offered by the canine arthritis treatment market. To understand the key segments in terms of their growth and performance in the global canine arthritis treatment market, Future Market Insights has developed a market attractiveness index. The resulting index will help identify the existing market opportunities in canine arthritis treatment market.

In the final section of the report, a ‘competitive landscape’ has been included to provide a dashboard view of the key companies operating in the global canine arthritis treatment market. This section is primarily designed to provide clients with an objective and detailed comparative assessment of the key providers specific to a market segment in the canine arthritis treatment market. However, this section also includes market strategies and SWOT analysis of the key players operating in the global canine arthritis treatment market.

Detailed profiles of canine arthritis treatment drug manufacturers are also included in the scope of the report to evaluate their long- and short-term strategies. Examples of some of the key players operating in the canine arthritis treatment market are Elanco (Eli Lilly and Company), Boehringer Ingelheim, Zoetis Inc., Vetoquinol S.A., Bayer AG, Aratana Therapeutics Inc., Norbrook Laboratories Limited, VetStem Biopharma, and Dechra Pharmaceuticals Plc, among others.

【レポートの目次】

1. Executive Summary

1.1. Market Overview

1.2. Market Analysis

1.3. FMI Analysis and Recommendations

1.4. Wheel of Fortune

2. Market Introduction

2.1. Market Taxonomy

2.2. Market Definition

2.3. Company Description and Canine Arthritis Treatment Market Research Coverage

3. Canine Arthritis Treatment Market Opportunity Analysis

3.1. Macro-Economic Factors

3.2. Opportunity Analysis

4. Market Background

4.1. Technology Evolution

4.2. List of Growth Hacking Manufacturers

4.3. Market Dynamics

4.3.1. Drivers

4.3.2. Restraints

4.3.3. Trends

4.4. Regulatory Scenario

5. Global Economic Outlook

5.1. Canine Arthritis Treatment Market Outlook

6. Key Inclusions

6.1. Canine Arthritis Treatment Market Analysis

6.2. Canine Osteoarthritis Treatment Scenario

7. North America Canine Arthritis Treatment Market Analysis 2013–2017 and Forecast 2018–2028

7.1. Introduction

7.2. Historical Market Size (US$ Mn) Analysis By Country, 2013-2017

7.2.1. U.S.

7.2.2. Canada

7.3. Market Size (US$ Mn) Forecast By Country, 2018-2028

7.4. Historical Market Size (US$ Mn) Trend Analysis By Treatment Type, 2013-2017

7.4.1. Non-steroidal anti-inflammatory medications (NSAIDs)

7.4.2. Opioids

7.4.3. Stem Cell Therapy

7.4.3.1. Allogeneic Stem Cell

7.4.3.2. Autologous Stem Cell

7.5. Market Size (US$ Mn) Forecast By Treatment Type, 2018-2028

7.6. Historical Market Size (US$ Mn) Trend Analysis By Route of Administration, 2013-2017

7.6.1. Oral

7.6.2. Injectable

7.7. Market Size (US$ Mn) Forecast By Route of Administration, 2018-2028

7.8. Historical Market Size (US$ Mn) Trend Analysis By End User, 2013-2017

7.8.1. Veterinary Hospitals & Clinics

7.8.2. Retail Pharmacies

7.8.3. Drug Stores

7.8.4. E-commerce

7.9. Market Size (US$ Mn) Forecast By End User, 2018-2028

7.10.Market Attractiveness Analysis

7.10.1. By Country

7.10.2. By Treatment Type

7.10.3. By Route of Administration

7.10.4. By End User

7.11.Drivers and Restraints: Impact Analysis

7.12.Key Market Participants – Intensity Mapping

8. Latin America Canine Arthritis Treatment Market Analysis 2013–2017 and Forecast 2018–2028

8.1. Introduction

8.2. Historical Market Size (US$ Mn) Analysis By Country, 2013-2017

8.2.1. Brazil

8.2.2. Mexico

8.2.3. Rest of Latin America

8.3. Market Size (US$ Mn) Forecast By Country, 2018-2028

8.4. Historical Market Size (US$ Mn) Trend Analysis By Treatment Type, 2013-2017

8.4.1. Non-steroidal anti-inflammatory medications (NSAIDs)

8.4.2. Opioids

8.4.3. Stem Cell Therapy

8.4.3.1. Allogeneic Stem Cell

8.4.3.2. Autologous Stem Cell

8.5. Market Size (US$ Mn) Forecast By Treatment Type, 2018-2028

8.6. Historical Market Size (US$ Mn) Trend Analysis By Route of Administration, 2013-2017

8.6.1. Oral

8.6.2. Injectable

8.7. Market Size (US$ Mn) Forecast By Route of Administration, 2018-2028

8.8. Historical Market Size (US$ Mn) Trend Analysis By End User, 2013-2017

8.8.1. Veterinary Hospitals & Clinics

8.8.2. Retail Pharmacies

8.8.3. Drug Stores

8.8.4. E-commerce

8.9. Market Size (US$ Mn) Forecast By End User, 2018-2028

8.10.Market Attractiveness Analysis

8.10.1. By Country

8.10.2. By Treatment Type

8.10.3. By Route of Administration

8.10.4. By End User

8.11.Drivers and Restraints: Impact Analysis

8.12. Key Market Participants – Intensity Mapping

9. Europe Canine Arthritis Treatment Market Analysis 2013–2017 and Forecast 2018–2028

9.1. Introduction

9.2. Historical Market Size (US$ Mn) Analysis By Country, 2013-2017

9.2.1. Germany

9.2.2. U.K

9.2.3. France

9.2.4. Italy

9.2.5. Spain

9.2.6. Russia

9.2.7. Rest of Western Europe

9.3. Market Size (US$ Mn) Forecast By Country, 2018-2028

9.4. Historical Market Size (US$ Mn) Trend Analysis By Treatment Type, 2013-2017

9.4.1. Non-steroidal anti-inflammatory medications (NSAIDs)

9.4.2. Opioids

9.4.3. Stem Cell Therapy

9.4.3.1. Allogeneic Stem Cell

9.4.3.2. Autologous Stem Cell

9.5. Market Size (US$ Mn) Forecast By Treatment Type, 2018-2028

9.6. Historical Market Size (US$ Mn) Trend Analysis By Route of Administration, 2013-2017

9.6.1. Oral

9.6.2. Injectable

9.7. Market Size (US$ Mn) Forecast By Route of Administration, 2018-2028

9.8. Historical Market Size (US$ Mn) Trend Analysis By End User, 2013-2017

9.8.1. Veterinary Hospitals & Clinics

9.8.2. Retail Pharmacies

9.8.3. Drug Stores

9.8.4. E-commerce

9.9. Market Size (US$ Mn) Forecast By End User, 2018-2028

9.10.Market Attractiveness Analysis

9.10.1. By Country

9.10.2. By Treatment Type

9.10.3. By Route of Administration

9.10.4. By End User

9.11.Drivers and Restraints: Impact Analysis

9.12.Key Market Participants – Intensity Mapping

10. Asia Pacific Excluding Japan (APEJ) Canine Arthritis Treatment Market Analysis 2013–2017 and Forecast 2018–2028

10.1.Introduction

10.2. Historical Market Size (US$ Mn) Analysis By Country, 2013-2017

10.2.1. China

10.2.2. India

10.2.3. Australia and New Zealand

10.2.4. ASEAN

10.2.5. Rest of APEJ

10.3.Market Size (US$ Mn) Forecast By Country, 2018-2028

10.4.Historical Market Size (US$ Mn) Trend Analysis By Treatment Type, 2013-2017

10.4.1. Non-steroidal anti-inflammatory medications (NSAIDs)

10.4.2. Opioids

10.4.3. Stem Cell Therapy

10.4.3.1. Allogeneic Stem Cell

10.4.3.2. Autologous Stem Cell

10.5.Market Size (US$ Mn) Forecast By Treatment Type, 2018-2028

10.6.Historical Market Size (US$ Mn) Trend Analysis By Route of Administration, 2013-2017

10.6.1. Oral

10.6.2. Injectable

10.7.Market Size (US$ Mn) Forecast By Route of Administration, 2018-2028

10.8.Historical Market Size (US$ Mn) Trend Analysis By End User, 2013-2017

10.8.1. Veterinary Hospitals & Clinics

10.8.2. Retail Pharmacies

10.8.3. Drug Stores

10.8.4. E-commerce

10.9.Market Size (US$ Mn) Forecast By End User, 2018-2028

10.10. Market Attractiveness Analysis

10.10.1. By Country

10.10.2. By Treatment Type

10.10.3. By Route of Administration

10.10.4. By End User

10.11. Drivers and Restraints: Impact Analysis

10.12. Key Market Participants – Intensity Mapping

11. Japan Canine Arthritis Treatment Market Analysis 2013–2017 and Forecast 2018–2028

11.1.Introduction

11.2.Historical Market Size (US$ Mn) Trend Analysis By Treatment Type, 2013-2017

11.2.1. Non-steroidal anti-inflammatory medications (NSAIDs)

11.2.2. Opioids

11.2.3. Stem Cell Therapy

11.2.3.1. Allogeneic Stem Cell

11.2.3.2. Autologous Stem Cell

11.3.Market Size (US$ Mn) Forecast By Treatment Type, 2018-2028

11.4.Historical Market Size (US$ Mn) Trend Analysis By Route of Administration, 2013-2017

11.4.1. Oral

11.4.2. Injectable

11.5.Market Size (US$ Mn) Forecast By Route of Administration, 2018-2028

11.6.Historical Market Size (US$ Mn) Trend Analysis By End User, 2013-2017

11.6.1. Veterinary Hospitals & Clinics

11.6.2. Retail Pharmacies

11.6.3. Drug Stores

11.6.4. E-commerce

11.7.Market Size (US$ Mn) Forecast By End User, 2018-2028

11.8.Market Attractiveness Analysis

11.8.1. By Treatment Type

11.8.2. By Route of Administration

11.8.3. By End User

11.9.Drivers and Restraints: Impact Analysis

11.10. Key Market Participants – Intensity Mapping

12. Middle East and Africa Canine Arthritis Treatment Market Analysis 2013–2017 and Forecast 2018–2028

12.1.Introduction

12.2. Historical Market Size (US$ Mn) Analysis By Country, 2013-2017

12.2.1. GCC Countries

12.2.2. South Africa

12.2.3. Rest of Middle East and Africa

12.3.Market Size (US$ Mn) Forecast By Country, 2018-2028

12.4.Historical Market Size (US$ Mn) Trend Analysis By Treatment Type, 2013-2017

12.4.1. Non-steroidal anti-inflammatory medications (NSAIDs)

12.4.2. Opioids

12.4.3. Stem Cell Therapy

12.4.3.1. Allogeneic Stem Cell

12.4.3.2. Autologous Stem Cell

12.5.Market Size (US$ Mn) Forecast By Treatment Type, 2018-2028

12.6.Historical Market Size (US$ Mn) Trend Analysis By Route of Administration, 2013-2017

12.6.1. Oral

12.6.2. Injectable

12.7.Market Size (US$ Mn) Forecast By Route of Administration, 2018-2028

12.8.Historical Market Size (US$ Mn) Trend Analysis By End User, 2013-2017

12.8.1. Veterinary Hospitals & Clinics

12.8.2. Retail Pharmacies

12.8.3. Drug Stores

12.8.4. E-commerce

12.9.Market Size (US$ Mn) Forecast By End User, 2018-2028

12.10. Market Attractiveness Analysis

12.10.1. By Country

12.10.2. By Treatment Type

12.10.3. By Route of Administration

12.10.4. By End User

12.11. Drivers and Restraints: Impact Analysis

12.12. Key Market Participants – Intensity Mapping

13. Forecast Factors: Relevance and Impact

14. Forecast Assumptions

15. Competition Analysis

15.1.Competition Dashboard

15.2.Company Deep Dive

15.2.1. Elanco (Eli Lily and Company)

15.2.1.1. Overview

15.2.1.2. Product and Application Portfolio

15.2.1.3. Production Footprint

15.2.1.4. Sales Footprint

15.2.1.5. Channel Footprint

15.2.1.6. Strategy

15.2.1.6.1. Marketing Strategy

15.2.1.6.2. Product Strategy

15.2.1.6.3. Channel Strategy

15.2.2. Ceva Santé Animale

15.2.2.1. Overview

15.2.2.2. Product and Application Portfolio

15.2.2.3. Production Footprint

15.2.2.4. Sales Footprint

15.2.2.5. Channel Footprint

15.2.2.6. Strategy

15.2.2.6.1. Marketing Strategy

15.2.2.6.2. Product Strategy

15.2.2.6.3. Channel Strategy

15.2.3. Vetoquinol S.A.

15.2.3.1. Overview

15.2.3.2. Product and Application Portfolio

15.2.3.3. Production Footprint

15.2.3.4. Sales Footprint

15.2.3.5. Channel Footprint

15.2.3.6. Strategy

15.2.3.6.1. Marketing Strategy

15.2.3.6.2. Product Strategy

15.2.3.6.3. Channel Strategy

15.2.4. Norbrook Laboratories Limited

15.2.4.1. Overview

15.2.4.2. Product and Application Portfolio

15.2.4.3. Production Footprint

15.2.4.4. Sales Footprint

15.2.4.5. Channel Footprint

15.2.4.6. Strategy

15.2.4.6.1. Marketing Strategy

15.2.4.6.2. Product Strategy

15.2.4.6.3. Channel Strategy

15.2.5. Aratana Therapeutics Inc.

15.2.5.1. Overview

15.2.5.2. Product and Application Portfolio

15.2.5.3. Production Footprint

15.2.5.4. Sales Footprint

15.2.5.5. Channel Footprint

15.2.5.6. Strategy

15.2.5.6.1.1. Marketing Strategy

15.2.5.6.1.2. Product Strategy

15.2.5.6.1.3. Channel Strategy

15.2.6. Boehringer Ingelheim

15.2.6.1. Overview

15.2.6.2. Product and Application Portfolio

15.2.6.3. Production Footprint

15.2.6.4. Sales Footprint

15.2.6.5. Channel Footprint

15.2.6.6. Strategy

15.2.6.6.1. Marketing Strategy

15.2.6.6.2. Product Strategy

15.2.6.6.3. Channel Strategy

15.2.7. Zoetis Inc.

15.2.7.1. Overview

15.2.7.2. Product and Application Portfolio

15.2.7.3. Production Footprint

15.2.7.4. Sales Footprint

15.2.7.5. Channel Footprint

15.2.7.6. Strategy

15.2.7.6.1. Marketing Strategy

15.2.7.6.2. Product Strategy

15.2.7.6.3. Channel Strategy

15.2.8. Bayer AG

15.2.8.1. Overview

15.2.8.2. Product and Application Portfolio

15.2.8.3. Production Footprint

15.2.8.4. Sales Footprint

15.2.8.5. Channel Footprint

15.2.8.6. Strategy

15.2.8.6.1. Marketing Strategy

15.2.8.6.2. Product Strategy

15.2.8.6.3. Channel Strategy

15.2.9. VetStem Biopharma

15.2.9.1. Overview

15.2.9.2. Product and Application Portfolio

15.2.9.3. Production Footprint

15.2.9.4. Sales Footprint

15.2.9.5. Channel Footprint

15.2.9.6. Strategy

15.2.9.6.1. Marketing Strategy

15.2.9.6.2. Product Strategy

15.2.9.6.3. Channel Strategy

15.2.10. Dechra Pharmaceuticals PLC

15.2.10.1. Overview

15.2.10.2. Product and Application Portfolio

15.2.10.3. Production Footprint

15.2.10.4. Sales Footprint

15.2.10.5. Channel Footprint

15.2.10.6. Strategy

15.2.10.6.1. Marketing Strategy

15.2.10.6.2. Product Strategy

15.2.10.6.3. Channel Strategy

16. Global Canine Arthritis Treatment Market Analysis 2013–2017 and Forecast 2018–2028 By Region

16.1. Introduction / Key Findings

16.2. Historical Market Size (US$ Mn) Analysis By Region

16.2.1. North America

16.2.2. Latin America

16.2.3. Europe

16.2.4. Asia Pacific Excluding Japan

16.2.5. Japan

16.2.6. Middle East and Afica

16.3. Market Size (US$ Mn) Forecast By Region, 2018-2028

16.4. Market Attractiveness Analysis By Region

17. Global Canine Arthritis Treatment Market Analysis 2013–2017 and Forecast 2018–2028, By Treatment Type

17.1. Introduction/Key Finding

17.2.Historical Market Size (US$ Mn) Trend Analysis By Treatment Type, 2013-2017

17.2.1. Non-steroidal anti-inflammatory medications (NSAIDs)

17.2.2. Opioids

17.2.3. Stem Cell Therapy

17.2.3.1. Allogeneic Stem Cell

17.2.3.2. Autologous Stem Cell

17.3. Market Size (US$ Mn) Forecast By Treatment Type, 2018-2028

17.4. Market Attractiveness Analysis By Treatment Type

18. Global Canine Arthritis Treatment Market Analysis 2013–2017 and Forecast 2018–2028, By Route of Administration

18.1. Introduction/Key Finding

18.2.Historical Market Size (US$ Mn) Trend Analysis By Route of Administration, 2013-2017

18.2.1. Oral

18.2.2. Injectable

18.3. Market Size (US$ Mn) Forecast By Route of Administration, 2018-2028

18.4. Market Attractiveness Analysis By Route of Administration

19. Global Canine Arthritis Treatment Market Analysis 2013–2017 and Forecast 2018–2028, By End User

19.1.Introduction/Key Finding

19.2.Historical Market Size (US$ Mn) Trend Analysis By End User, 2013-2017

19.2.1. Veterinary Hospitals & Clinics

19.2.2. Retail Pharmacies

19.2.3. Drug Stores

19.2.4. E-commerce

19.3.Market Size (US$ Mn) Forecast By End User, 2018-2028

19.4.Market Attractiveness Analysis By End User

20. Global Canine Arthritis Treatment Market Analysis 2013–2017 and Forecast 2018–2028

20.1.Market Value Share Analysis By All Segment

20.2.Y-o-Y Growth Analysis By All Segment

20.3.Absolute $ Opportunity

21. Assumptions and Acronyms Used

22. Research Methodology

【レポートのキーワード】

犬関節炎治療薬

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 犬関節炎治療薬の世界市場(Canine Arthritis Treatment Market: Asia Pacific Excluding Japan to Register the Fastest Growth During the Forecast Period: Global Industry Analysis (2013 - 2017) and Opportunity Assessment (2018 - 2028))]についてメールでお問い合わせはこちらでお願いします。

グローバル市場調査/マーケットリサーチ会社：レポート販売と委託調査サービス提供 GlobalResearch.jp